GOLDMAN SACHS GROUP INC - X4 PHARMACEUTICALS INC ownership

X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 100 filers reported holding X4 PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of X4 PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$99,291
-93.3%
171,190
-83.8%
0.00%
Q1 2024$1,471,913
+2311.7%
1,058,930
+1354.8%
0.00%
Q4 2023$61,033
+12.9%
72,788
+46.8%
0.00%
Q3 2023$54,056
-91.7%
49,593
-85.2%
0.00%
Q2 2023$648,816
+793.3%
334,441
+300.6%
0.00%
Q1 2023$72,629
+33.0%
83,482
+51.8%
0.00%
Q4 2022$54,595
+57368.4%
54,980
-0.7%
0.00%
Q3 2022$95
-99.8%
55,380
+164.4%
0.00%
Q4 2021$48,000
-12.7%
20,949
+100.0%
0.00%
Q3 2021$55,000
-84.3%
10,475
-80.6%
0.00%
Q2 2021$351,000
-50.9%
54,007
-35.0%
0.00%
Q1 2021$715,000
+98.6%
83,037
+48.3%
0.00%
Q4 2020$360,000
+3.4%
56,006
+8.9%
0.00%
Q3 2020$348,000
+18.4%
51,418
+62.8%
0.00%
Q2 2020$294,000
+107.0%
31,583
+123.2%
0.00%
Q1 2020$142,000
-30.7%
14,150
-26.0%
0.00%
Q4 2019$205,000
+8.5%
19,125
+28.8%
0.00%
Q3 2019$189,000
-60.6%
14,845
-53.6%
0.00%
Q2 2019$480,00032,0250.00%
Other shareholders
X4 PHARMACEUTICALS INC shareholders Q2 2023
NameSharesValueWeighting ↓
CVI Holdings, LLC 2,300,315$4,462,6114.69%
Stonepine Capital Management, LLC 4,605,263$8,934,2103.22%
Bain Capital Life Sciences Investors, LLC 15,960,588$30,963,5413.19%
Tri Locum Partners LP 4,099,943$7,953,8892.96%
NEA Management Company, LLC 14,986,793$29,074,3782.22%
Lynwood Capital Management Inc. 525,000$1,018,5001.29%
Parkman Healthcare Partners LLC 3,766,593$7,307,1901.27%
Sio Capital Management, LLC 1,749,003$3,393,0660.86%
New Leaf Venture Partners, L.L.C. 335,000$649,9000.56%
KINGDON CAPITAL MANAGEMENT, L.L.C. 1,973,683$3,828,9450.36%
View complete list of X4 PHARMACEUTICALS INC shareholders